Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:9952 |
Name | acute lymphoblastic leukemia |
Definition | A acute leukemia that is characterized by over production of lymphoblasts. |
Source | DiseaseOntology.org |
Alt Ids | DOID:5600 |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia acute leukemia acute lymphoblastic leukemia |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
CDKN2A mut NRAS act mut | Trametinib | acute lymphoblastic leukemia | resistant | detail... |
KMT2A rearrange | Cytarabine + Panobinostat | acute lymphoblastic leukemia | sensitive | detail... |
KMT2A rearrange | Cytarabine + Mocetinostat | acute lymphoblastic leukemia | sensitive | detail... |
KMT2A rearrange | Cytarabine + Dacinostat | acute lymphoblastic leukemia | sensitive | detail... |
KMT2A rearrange | Cytarabine + Romidepsin | acute lymphoblastic leukemia | sensitive | detail... |
KMT2A rearrange | Romidepsin | acute lymphoblastic leukemia | decreased response | detail... |
KMT2A rearrange | Cytarabine | acute lymphoblastic leukemia | sensitive | detail... |
PTEN loss | BGT226 | acute lymphoblastic leukemia | sensitive | detail... |
KMT2A rearrange | CYC065 | acute lymphoblastic leukemia | predicted - sensitive | detail... |
NRAS G12S | IHMT-RAF-128 | acute lymphoblastic leukemia | sensitive | detail... |
NRAS A146T | IHMT-RAF-128 | acute lymphoblastic leukemia | sensitive | detail... |
KMT2A rearrange | Fingolimod | acute lymphoblastic leukemia | sensitive | detail... |
ABL1 fusion | Dasatinib | acute lymphoblastic leukemia | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00084695 | Phase II | Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone | Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases | Unknown status | USA | 0 |
NCT00513474 | Phase I | Rasburicase Methotrexate Sirolimus Cyclosporine Tacrolimus Filgrastim Busulfan + Cyclophosphamide + Etoposide | Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant | Completed | USA | 0 |
NCT00549848 | Phase III | Daunorubicin + Pegaspargase + Vincristine Sulfate Cytarabine Mercaptopurine Thioguanine Clofarabine + Cyclophosphamide + Etoposide Methotrexate Dasatinib Doxorubicin Dexamethasone | Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | Completed | USA | 0 |
NCT00550992 | Phase I | Busulfan Melphalan Mercaptopurine Cytarabine + Etoposide + Mitoxantrone Cyclophosphamide + Methotrexate + Pegaspargase + Vincristine Sulfate Thioguanine Cyclosporine anti-thymocyte globulin Daunorubicin Leucovorin | Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia | Unknown status | USA | NLD | ITA | GBR | FRA | DEU | CZE | BEL | AUT | 0 |
NCT00679536 | Phase Ib/II | anti-thymocyte globulin + Busulfan + Fludarabine | Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors | Unknown status | USA | 0 |
NCT00777036 | Phase II | Dasatinib | A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib | Active, not recruiting | USA | ROU | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BRA | AUS | ARG | 6 |
NCT00857389 | Phase II | Cyclophosphamide Filgrastim Tacrolimus Thiotepa anti-thymocyte globulin + Busulfan + Clofarabine Methotrexate | Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies | Completed | USA | 0 |
NCT00866281 | Phase Ib/II | Midostaurin | A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia | Terminated | USA | SWE | NLD | ITA | FRA | 0 |
NCT00908167 | Phase I | Clofarabine + Cytarabine + Sorafenib | Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies | Completed | USA | 0 |
NCT00990249 | Phase II | anti-thymocyte globulin + Busulfan + Clofarabine | Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation | Completed | USA | 0 |
NCT01028716 | Phase II | Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Terminated | USA | 0 |
NCT01077544 | Phase I | Nilotinib | A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL) | Completed | NLD | ITA | GBR | FRA | 0 |
NCT01085617 | Phase III | Palifermin Cyclophosphamide + Cytarabine + Daunorubicin + Etoposide + Fludarabine + Imatinib + Melphalan + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine Sulfate Cyclophosphamide + Cytarabine + Daunorubicin + Etoposide + Fludarabine + Melphalan + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine Sulfate Cyclophosphamide + Cytarabine + Daunorubicin + Etoposide + Fludarabine + Imatinib + Melphalan + Mercaptopurine + Methotrexate + Pegaspargase + Rituximab + Vincristine Sulfate Cyclophosphamide + Cytarabine + Daunorubicin + Etoposide + Fludarabine + Melphalan + Mercaptopurine + Methotrexate + Nelarabine + Pegaspargase + Vincristine Sulfate | Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (UKALL14) | Active, not recruiting | 0 | |
NCT01162551 | Phase II | Methotrexate + Sirolimus | Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma | Completed | USA | 0 |
NCT01187810 | Phase I | Fenretinide Cytarabine Methotrexate | Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL | Terminated | USA | 0 |
NCT01251575 | Phase II | Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus | Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant | Completed | USA | DNK | 0 |
NCT01256398 | Phase II | Dexamethasone Dasatinib Tacrolimus Cyclophosphamide + Fludarabine Filgrastim Mercaptopurine + Methotrexate + Vincristine Sulfate Melphalan Cytarabine + Daunorubicin + Etoposide Pegfilgrastim Alemtuzumab Leucovorin | Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | Completed | USA | 0 |
NCT01266083 | Phase II | WT1 vaccine | Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) | Completed | USA | 0 |
NCT01319981 | Phase II | Pegfilgrastim Imatinib Filgrastim Rituximab Doxorubicin Dexamethasone Vincristine Sulfate Cyclophosphamide | Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia | Completed | USA | 0 |
NCT01321346 | Phase I | Cytarabine Panobinostat | A Study Of Panobinostat In Children With Refractory Hematologic Malignancies | Completed | USA | 0 |
NCT01324180 | Phase I | Metformin Dexamethasone + Doxorubicin + Pegaspargase + Vincristine Sulfate | Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL) | Completed | USA | 0 |
NCT01338987 | Phase II | Tacrolimus Busulfan Methotrexate Leuprolide Cyclophosphamide Fludarabine | Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation | Completed | USA | 0 |
NCT01371630 | Phase Ib/II | Inotuzumab ozogamicin Cyclophosphamide + Cytarabine + Inotuzumab ozogamicin + Methotrexate + Vincristine Sulfate Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Rituximab Cytarabine + Inotuzumab ozogamicin + Methotrexate | Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT01424982 | Phase II | Cytarabine + Methotrexate + Ponatinib Rituximab Ponatinib + Vincristine Sulfate Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine Sulfate Leucovorin | Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia | Active, not recruiting | USA | 0 |
NCT01483690 | Phase Ib/II | Pegaspargase Methotrexate Dexamethasone Vincristine Sulfate Decitabine Mitoxantrone | A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL | Terminated | USA | AUS | 0 |
NCT01491763 | FDA approved | Cytarabine + Etoposide + Imatinib + Mercaptopurine + Methotrexate Daunorubicin + Imatinib + Prednisone + Vincristine Sulfate | Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE | Unknown status | ESP | 0 |
NCT01523977 | Phase I | Prednisone Everolimus Vincristine Sulfate Doxorubicin Pegaspargase | Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL | Completed | USA | 0 |
NCT01614197 | Phase I | Etoposide Cyclophosphamide Prednisone Cytarabine Temsirolimus Methotrexate | A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma | Completed | USA | CAN | AUS | 0 |
NCT01620216 | Phase II | Sunitinib Dasatinib Nilotinib Ponatinib Sorafenib | Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients | Terminated | USA | 0 |
NCT01621477 | Phase II | Plerixafor Tacrolimus Mycophenolate mofetil anti-thymocyte globulin + Busulfan + Clofarabine Cyclophosphamide + Cytarabine | T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant | Terminated | USA | 0 |
NCT01634217 | Phase I | Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation | Completed | USA | 0 | |
NCT01658007 | Phase I | Sirolimus | Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma | Terminated | USA | 0 |
NCT01685411 | Phase 0 | Busulfan + Cyclophosphamide Filgrastim Allopurinol Mycophenolate mofetil anti-thymocyte globulin Tacrolimus Levetiracetam | Busulfan and Cyclophosphamide Followed By ALLO BMT | Terminated | USA | 0 |
NCT01744223 | Phase Ib/II | Rimiducid Rivogenlecleucel | Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant | Active, not recruiting | USA | 0 |
NCT01746849 | Phase II | Leuprolide Cyclophosphamide Thiotepa Palifermin | Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation | Active, not recruiting | USA | 0 |
NCT01769209 | Phase II | Bortezomib Cytarabine + Methotrexate Dexamethasone + Doxorubicin + Pegaspargase + Vincristine Sulfate | Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | Completed | USA | 0 |
NCT01829971 | Phase I | MRX34 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | Terminated | USA | 1 |
NCT01841333 | Phase II | Glasdegib | PF-04449913 For Patients With Acute Leukemia at High Risk of Relapse After Donor Stem Cell Transplant | Completed | USA | 0 |
NCT01885689 | Phase II | Clofarabine + Melphalan | Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia or Acute Leukemia in Remission | Active, not recruiting | USA | 0 |
NCT01885897 | Phase Ib/II | Nogapendekin alfa inbakicept | IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT | Completed | USA | 0 |
NCT01925131 | Phase I | Cyclophosphamide + Prednisone + Vincristine Sulfate Inotuzumab ozogamicin | S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia | Completed | USA | 0 |
NCT01943682 | Phase I | CPX-351 | Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma | Completed | USA | 0 |
NCT02003222 | Phase III | Cytarabine Daunorubicin + Dexamethasone + Methotrexate + Pegaspargase + Vincristine Sulfate Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Cyclophosphamide + Cytarabine + Mercaptopurine + Pegaspargase Methotrexate + Pegaspargase Cytarabine + Etoposide + Methotrexate Rituximab Blinatumomab | Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia | Active, not recruiting | USA | ISR | CAN | 1 |
NCT02043587 | Phase II | Rituximab Pegaspargase Methotrexate Cytarabine Leucovorin Cyclophosphamide Dasatinib Daunorubicin Vincristine Sulfate Etoposide | Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma | Terminated | USA | 0 |
NCT02071927 | Phase I | Telaglenastat | Study of the Glutaminase Inhibitor CB-839 in Leukemia | Completed | USA | 0 |
NCT02081378 | Phase I | Asciminib Asciminib + Imatinib Asciminib + Dasatinib Asciminib + Nilotinib | A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL | Completed | USA | NLD | ITA | FRA | ESP | DEU | AUS | 3 |
NCT02083250 | Phase I | anti-thymocyte globulin Vorinostat Busulfan + Clofarabine + Fludarabine | Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia | Completed | USA | 0 |
NCT02089230 | Phase Ib/II | Binimetinib | MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy | Terminated | USA | 0 |
NCT02091245 | Phase I | Selinexor | Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML | Active, not recruiting | USA | 0 |
NCT02101853 | Phase III | Blinatumomab Leucovorin + Pegaspargase + Vincristine Sulfate Mercaptopurine + Thioguanine Asparaginase + Cyclophosphamide + Etoposide Cytarabine + Dexamethasone + Methotrexate | Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia | Active, not recruiting | USA | NZL | CAN | AUS | 1 |
NCT02129062 | Phase II | Ibrutinib | Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia | Terminated | USA | 0 |
NCT02141828 | Phase I | Pinometostat | A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene | Completed | USA | CAN | 0 |
NCT02143635 | Phase I | Siremadlin | Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt | Completed | USA | NLD | FRA | ESP | DEU | 3 |
NCT02146924 | Phase I | Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia | Active, not recruiting | USA | 0 | |
NCT02181478 | Phase I | Fludarabine Cyclophosphamide | Intra-Osseous Co-Transplant of UCB and hMSC | Completed | USA | 0 |
NCT02199184 | Phase II | Cyclophosphamide + Doxorubicin + Etoposide + Ofatumumab + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate | Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia | Completed | USA | 0 |
NCT02200380 | Phase II | Plerixafor CDX-301 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | Terminated | USA | 0 |
NCT02203903 | Phase I | MultiTAA-specific T cells | Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE) | Recruiting | USA | 0 |
NCT02212561 | Phase Ib/II | Selinexor Cytarabine Cytarabine + Dexamethasone + Methotrexate Fludarabine | Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome | Completed | USA | 0 |
NCT02269579 | Phase II | CPX-351 | Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment | Withdrawn | USA | 0 |
NCT02319369 | Phase I | Milademetan | Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies | Terminated | USA | 0 |
NCT02356159 | Phase Ib/II | Cytarabine + Fludarabine Palifermin Prednisone Filgrastim Methotrexate + Sirolimus + Tacrolimus Doxorubicin + Etoposide + Fludarabine + Vincristine Sulfate Cyclophosphamide + Fludarabine Rituximab | Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation | Active, not recruiting | USA | 0 |
NCT02454270 | Phase II | JNJ-64052781 | A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies | Terminated | USA | ISR | FRA | ESP | BEL | 0 |
NCT02475707 | Phase I | MultiTAA-specific T cells | Administration of Donor MultiTAA-Specific T Cells for ALL (STELLA) | Active, not recruiting | USA | 0 |
NCT02484430 | Phase II | Sapanisertib | TORC1/2 Inhibitor INK128 in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia | Active, not recruiting | USA | 0 |
NCT02487459 | Phase I | Rivogenlecleucel Rimiducid | Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies | Withdrawn | USA | 0 |
NCT02494882 | Phase I | Dasatinib + Dexamethasone + Ruxolitinib | Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older | Active, not recruiting | USA | 0 |
NCT02518750 | Phase II | Bortezomib + Dexamethasone + Panobinostat Pegaspargase Mercaptopurine Nelarabine Mitoxantrone Vincristine Sulfate Cyclophosphamide + Etoposide Cytarabine + Methotrexate + Prednisone Clofarabine | Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma | Terminated | USA | 0 |
NCT02529813 | Phase I | Cyclophosphamide + Fludarabine + Tisagenlecleucel | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | Completed | USA | 0 |
NCT02535806 | Phase II | Vincristine Sulfate Bortezomib Pegaspargase Methotrexate Cytarabine Mitoxantrone Prednisone | Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults | Terminated | USA | 0 |
NCT02538926 | Phase II | Imatinib Rituximab Cyclophosphamide Prednisone Doxorubicin + Etoposide + Vincristine Sulfate Asparaginase | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | Withdrawn | USA | 0 |
NCT02553460 | Phase II | Cyclophosphamide Mitoxantrone Dexamethasone Bortezomib Etoposide Vincristine Sulfate Pegaspargase Vorinostat Cytarabine Methotrexate Leucovorin | Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I | Active, not recruiting | USA | CAN | 0 |
NCT02611492 | Phase III | Mercaptopurine + Methotrexate + Nilotinib Cytarabine + Dexamethasone + Filgrastim + Methotrexate + Nilotinib + Vincristine Sulfate Imatinib | A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults (GRAAPH2014) | Recruiting | FRA | 0 |
NCT02614066 | Phase Ib/II | axicabtagene ciloleucel | A Study Evaluating KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3) (ZUMA-3) | Completed | USA | NLD | FRA | DEU | CAN | 0 |
NCT02625480 | Phase Ib/II | axicabtagene ciloleucel | A Multi-Center Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-4) | Active, not recruiting | USA | SWE | POL | NLD | ITA | FRA | ESP | DEU | CZE | CAN | BEL | 0 |
NCT02629692 | Phase Ib/II | K0706 | Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to >=3 Prior CML Therapies | Active, not recruiting | USA | TUR | ROU | ITA | HUN | GBR | FRA | ESP | BEL | 2 |
NCT02706392 | Phase I | Cyclophosphamide + Fludarabine + ROR1 CAR-T cells | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | Terminated | USA | 0 |
NCT02723994 | Phase II | Prednisone Dexamethasone + Doxorubicin Leucovorin Mercaptopurine + Thioguanine Asparaginase + Cytarabine Ruxolitinib Cyclophosphamide + Methotrexate + Pegaspargase + Vincristine Sulfate | A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia | Active, not recruiting | USA | CAN | 1 |
NCT02727803 | Phase II | anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells | Personalized NK Cell Therapy in CBT | Recruiting | USA | 0 |
NCT02746952 | Phase I | UCART19 | Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia (CALM) | Completed | USA | GBR | FRA | 1 |
NCT02767934 | Phase II | Pembrolizumab | Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia | Terminated | USA | 0 |
NCT02790515 | Phase II | Sirolimus anti-thymocyte globulin Blinatumomab Tacrolimus Thiotepa Melphalan Fludarabine Cyclophosphamide Mesna Rituximab Filgrastim | Provision of TCRgammadelta T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation | Active, not recruiting | USA | 0 |
NCT02793544 | Phase II | Cyclophosphamide Busulfan Sirolimus Mycophenolate mofetil Mesna Fludarabine | HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide | Completed | USA | 0 |
NCT02795520 | Phase Ib/II | OTS167 | Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia | Terminated | USA | 0 |
NCT02815059 | Phase I | Dasatinib + Ibrutinib + Prednisone | Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone | Withdrawn | USA | 0 |
NCT02819804 | Phase I | Dasatinib + Nivolumab | Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | Terminated | USA | 0 |
NCT02861040 | Phase I | Vincristine Sulfate + Volasertib | Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | Withdrawn | USA | 0 |
NCT02879695 | Phase I | Blinatumomab + Ipilimumab + Nivolumab | Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia | Active, not recruiting | USA | 0 |
NCT02881086 | Phase III | Rituximab Doxorubicin Cytarabine Mercaptopurine Nelarabine Methotrexate Pegaspargase Cyclophosphamide Vindesine Vincristine Sulfate Daunorubicin Dexamethasone | Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | Active, not recruiting | DEU | 0 |
NCT02890758 | Phase I | Nogapendekin alfa inbakicept | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | Completed | USA | 0 |
NCT02906371 | Phase I | Tocilizumab | Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome | Completed | USA | 0 |
NCT02930109 | Phase Ib/II | Cytarabine + Triciribine | A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia | Completed | USA | 0 |
NCT02931110 | Phase I | CBL0137 | Study of IV CBL0137 in Previously Treated Hematological Subjects | Terminated | USA | 0 |
NCT02935543 | Phase II | CART19 cells | CART19 in Patient With ALL | Terminated | USA | 0 |
NCT02960646 | Phase I | Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Completed | USA | 0 |
NCT02997761 | Phase II | Blinatumomab + Ibrutinib | Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT03007147 | Phase III | Pegaspargase Methotrexate Leucovorin Cytarabine Mercaptopurine Thioguanine Vincristine Sulfate Cyclophosphamide Imatinib Ifosfamide Dexrazoxane Daunorubicin Dexamethasone Methylprednisolone Etoposide Prednisolone Doxorubicin | Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | Active, not recruiting | USA | SWE | NZL | NLD | ITA | ISR | FRA | FIN | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 4 |
NCT03020030 | Phase III | Nelarabine Dexrazoxane Asparaginase Vincristine Sulfate Cyclophosphamide Cytarabine Mercaptopurine Pegaspargase Methotrexate Etoposide Doxorubicin Dexamethasone Prednisone Dasatinib Leucovorin | Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents | Active, not recruiting | USA | CAN | 0 |
NCT03023046 | Phase II | Rituximab Doxorubicin Etoposide Imatinib Dasatinib Cyclophosphamide Prednisone Vincristine Sulfate | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | Completed | USA | 0 |
NCT03056339 | Phase Ib/II | Cyclophosphamide + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK | Umbilical & Cord Blood (CB)- Derived CAR-Engineered NK Cells for B Lymphoid Malignancies | Completed | USA | 0 |
NCT03069469 | Phase I | Vimseltinib | Study of DCC-3014 in Patients With Advanced Malignancies | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | CAN | AUS | 0 |
NCT03071276 | Phase II | Cytarabine + Fludarabine + Methotrexate + Prednisone + Selinexor | Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT03085173 | Phase I | EGFRt/19-28z/4-1BBL CAR T cells | A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT03094611 | Phase II | Inotuzumab ozogamicin | Study of Low Dose Inotuzumab Ozogamicin in Patients With Relapsed and Refractory CD22 Positive Acute Lymphocytic Leukemia | Terminated | USA | 0 |
NCT03103971 | Phase I | Cyclophosphamide + Fludarabine + HuJCAR014 | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | Terminated | USA | 0 |
NCT03104491 | Phase Ib/II | Inotuzumab ozogamicin | Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia | Recruiting | USA | 0 |
NCT03110354 | Phase I | DS-3201b | DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL) | Terminated | USA | 0 |
NCT03117751 | Phase II | Cyclophosphamide Vincristine Sulfate Idarubicin Blinatumomab Doxorubicin Clofarabine Vorinostat Ruxolitinib Prednisone Bortezomib Etoposide Dasatinib Daunorubicin Dexamethasone Rituximab Methotrexate Cytarabine Mercaptopurine Pegaspargase | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | Active, not recruiting | USA | AUS | 0 |
NCT03128034 | Phase Ib/II | Cyclosporine + Fludarabine + Mycophenolate mofetil + Sirolimus | 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome | Suspended | USA | 0 |
NCT03132454 | Phase I | Decitabine + Palbociclib Dexamethasone + Palbociclib Palbociclib Palbociclib + Sorafenib | Study of Palbociclib Alone and in Combination in Patients With Relapsed and Refractory (R/R) Leukemias | Recruiting | USA | 0 |
NCT03147612 | Phase II | Pegfilgrastim Blinatumomab Vincristine Sulfate Rituximab Filgrastim Ponatinib Cyclophosphamide Methotrexate Cytarabine | Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia | Active, not recruiting | USA | 0 |
NCT03150693 | Phase III | Rituximab Doxorubicin Mercaptopurine Methotrexate Cyclophosphamide + Cytarabine Thioguanine Allopurinol Daunorubicin Dexamethasone Vincristine Sulfate Inotuzumab ozogamicin | Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia | Suspended | USA | CAN | 0 |
NCT03160079 | Phase Ib/II | Blinatumomab + Pembrolizumab | Blinatumomab and Pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia With High Marrow Lymphoblasts | Active, not recruiting | USA | 0 |
NCT03181126 | Phase I | Navitoclax + Venetoclax | A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed Acute Lymphoblastic Leukemia | Completed | USA | AUS | 0 |
NCT03241940 | Phase I | Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells | Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies | Recruiting | USA | 0 |
NCT03263572 | Phase II | Blinatumomab + Cytarabine + Methotrexate + Ponatinib | Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT03263637 | Phase I | AZD4573 | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | Completed | NLD | GBR | DEU | 0 |
NCT03267186 | Phase II | Ibrutinib | Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant | Completed | USA | 0 |
NCT03286114 | Phase I | Pembrolizumab | Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab | Terminated | USA | 0 |
NCT03319901 | Phase I | Cytarabine Mercaptopurine Methotrexate Cyclophosphamide Venetoclax Doxorubicin Etoposide Vincristine Sulfate | Venetoclax and Chemotherapy In ALL | Recruiting | USA | 0 |
NCT03326921 | Phase I | Fludarabine HA-1 TCR T cells | HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | Recruiting | USA | 0 |
NCT03349281 | Phase I | Dexamethasone + Doxorubicin + MLN4924 + Pegaspargase + Vincristine Sulfate | Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia | Completed | USA | 0 |
NCT03386513 | Phase Ib/II | IMGN632 | Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | 0 |
NCT03414450 | Phase I | Dasatinib + ETC-1907206 | Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies | Withdrawn | USA | 1 |
NCT03460522 | Phase II | Inotuzumab ozogamicin | Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL | Recruiting | DEU | 0 |
NCT03472573 | Phase I | Dexamethasone + Palbociclib | Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia | Completed | USA | 0 |
NCT03480360 | Phase III | Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | Active, not recruiting | USA | 0 |
NCT03483324 | Phase I | AB-110 | Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation | Completed | USA | 0 |
NCT03488225 | Phase II | Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Cytarabine + Leucovorin + Methotrexate Inotuzumab ozogamicin Ofatumumab Rituximab Cytarabine + Doxorubicin + Methotrexate + Vincristine Sulfate Pegfilgrastim Cyclophosphamide + Dexamethasone + Mesna | Hyper-CVAD in Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With Acute Lymphocytic Leukemia | Terminated | USA | 0 |
NCT03504644 | Phase Ib/II | Venetoclax + Vincristine Sulfate | Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia | Active, not recruiting | USA | 1 |
NCT03512405 | Phase Ib/II | Blinatumomab + Pembrolizumab | Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT03515200 | Phase I | Cytarabine + Dexamethasone + Methotrexate Bortezomib + Dasatinib + Dexamethasone + Doxorubicin + Palbociclib | Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia | Terminated | USA | 0 |
NCT03571321 | Phase I | Pegaspargase Methotrexate Cytarabine Mercaptopurine Thioguanine Ruxolitinib Cyclophosphamide Dexamethasone Vincristine Sulfate Rituximab Doxorubicin | Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT03575325 | Phase II | CPX-351 | Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia | Completed | USA | 0 |
NCT03576547 | Phase Ib/II | Dexamethasone + Ponatinib + Rituximab + Venetoclax Dexamethasone + Ponatinib + Venetoclax | Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia | Completed | USA | 0 |
NCT03579888 | Phase I | CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells + Cyclophosphamide + Fludarabine | CD19-Specific T Cells Post AlloSCT | Terminated | USA | 0 |
NCT03589326 | Phase III | Cytarabine + Methotrexate + Ponatinib Dexamethasone + Ponatinib + Vincristine Sulfate Ponatinib + Prednisone + Vincristine Sulfate Dexamethasone + Imatinib + Vincristine Sulfate Cytarabine + Imatinib + Methotrexate Imatinib + Prednisone + Vincristine Sulfate | A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia | Active, not recruiting | USA | TUR | POL | ITA | GRC | FRA | FIN | ESP | CAN | BRA | BGR | AUT | AUS | ARG | 6 |
NCT03592576 | Expanded access | Navitoclax | Expanded Access to Navitoclax | No longer available | 0 | |
NCT03670966 | Phase Ib/II | BC8-B10 + Cyclophosphamide + Fludarabine Cyclophosphamide + Filgrastim + Mycophenolate mofetil + Sirolimus + Tacrolimus | 211At-BC8-B10 and Donor Stem Cell Transplant in Treating Relapsed or Refractory AML, ALL, or Myelodysplastic Syndrome | Suspended | USA | 0 |
NCT03674411 | Phase II | Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | Active, not recruiting | USA | 0 |
NCT03698552 | Phase Ib/II | ADCT-602 | ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT03739606 | Phase II | Flotetuzumab | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | Withdrawn | 0 | |
NCT03739814 | Phase II | Blinatumomab + Inotuzumab ozogamicin | Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT03740334 | Phase I | Dexamethasone + Ribociclib Dexamethasone + Everolimus + Ribociclib | Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL | Active, not recruiting | USA | 0 |
NCT03751709 | Phase I | Blinatumomab | Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL | Active, not recruiting | USA | 0 |
NCT03765177 | Phase Ib/II | CLIC-1901 | CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies (CLIC-01) | Recruiting | CAN | 0 |
NCT03807063 | Phase I | Rimiducid Rivogenlecleucel | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant | Withdrawn | USA | 0 |
NCT03808610 | Phase Ib/II | Cyclophosphamide + Dexamethasone + Venetoclax + Vincristine Sulfate Cyclophosphamide + Dexamethasone + Rituximab + Venetoclax + Vincristine Sulfate Cytarabine + Methotrexate + Venetoclax Cytarabine + Methotrexate + Rituximab + Venetoclax Nelarabine + Pegaspargase Prednisone + Venetoclax + Vincristine Sulfate | Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia | Active, not recruiting | USA | 0 |
NCT03821610 | Phase II | Alemtuzumab + Cyclophosphamide + Mesna Alemtuzumab + Fludarabine + Melphalan | A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC) (ALL-RIC) | Active, not recruiting | GBR | 0 |
NCT03826992 | Phase I | CPX-351 + Venetoclax | Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia | Recruiting | USA | 0 |
NCT03829540 | Phase I | CD4CAR | CD4CAR for CD4+ Leukemia and Lymphoma | Recruiting | USA | 0 |
NCT03851081 | Phase Ib/II | Inotuzumab ozogamicin + Vincristine sulfate liposome | Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia | Withdrawn | USA | 0 |
NCT03853616 | Phase Ib/II | MB-CART19.1 | MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) | Recruiting | DEU | 0 |
NCT03856216 | Phase II | Methotrexate Filgrastim + Methotrexate + Rituximab Rituximab Bendamustine + Fludarabine + Inotuzumab ozogamicin + Tacrolimus Filgrastim + Methotrexate Inotuzumab ozogamicin Fludarabine + Inotuzumab ozogamicin + Melphalan + Tacrolimus anti-thymocyte globulin | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation | Recruiting | USA | 0 |
NCT03885947 | Phase I | Cyclophosphamide + Fludarabine + Thiotepa | VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies | Completed | USA | 0 |
NCT03913026 | Phase II | ECT-001 cord blood cells Mycophenolate mofetil Tacrolimus Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine + Thiotepa | UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia | Active, not recruiting | CAN | 0 |
NCT03914625 | Phase III | Cytarabine + Leucovorin + Methotrexate + Pegaspargase + Vincristine Sulfate Blinatumomab + Dexamethasone + Methotrexate Leucovorin + Mercaptopurine + Methotrexate + Vincristine Sulfate Blinatumomab + Methotrexate Mercaptopurine + Methotrexate + Vincristine Sulfate Blinatumomab + Dexamethasone + Leucovorin + Methotrexate Methotrexate + Pegaspargase + Vincristine Sulfate Blinatumomab + Leucovorin + Methotrexate Blinatumomab + Dexamethasone + Leucovorin Mercaptopurine + Methotrexate + Prednisolone + Vincristine Sulfate Dexamethasone + Doxorubicin + Methotrexate + Pegaspargase + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Leucovorin + Methotrexate + Pegaspargase + Thioguanine + Vincristine Sulfate Cyclophosphamide + Cytarabine + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine Sulfate Cyclophosphamide + Cytarabine + Leucovorin + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine Sulfate Leucovorin + Methotrexate + Vincristine Sulfate Methotrexate + Vincristine Sulfate Dexamethasone + Mercaptopurine + Methotrexate + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Pegaspargase + Thioguanine + Vincristine Sulfate Cytarabine + Dexamethasone + Methotrexate + Pegaspargase + Vincristine Sulfate Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Dexamethasone + Leucovorin + Mercaptopurine + Methotrexate + Vincristine Sulfate | Blinatumomab in Combination With Chemotherapy in Treating Patients With or Without Down Syndrome and Newly Diagnosed, Standard Risk B-Lymphoblastic Leukemia or Localized B-Lymphoblastic Lymphoma | Active, not recruiting | USA | NZL | CAN | AUS | 1 |
NCT03934372 | Phase Ib/II | Ponatinib | Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors | Recruiting | SWE | NLD | ITA | GBR | FRA | ESP | DNK | DEU | BEL | 0 |
NCT03938987 | Phase Ib/II | Cyclophosphamide + Fludarabine Anti-CD19 CAR-T cells | Anti-CD19, Dual Co-stimulatory (4-1BB, CD3zeta) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (ACIT001/EXC002) | Recruiting | CAN | 0 |
NCT03991884 | Phase I | Cyclophosphamide + Doxorubicin + Etoposide + Inotuzumab ozogamicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Inotuzumab ozogamicin + Prednisone + Vincristine Sulfate | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia | Completed | USA | 0 |
NCT04065399 | Phase Ib/II | Revumenib | A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101) | Recruiting | USA | NLD | LTU | ITA | ISR | FRA | ESP | DEU | CAN | AUS | 1 |
NCT04088864 | Phase I | Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine | CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies | Active, not recruiting | USA | 0 |
NCT04088890 | Phase I | Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine | Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies | Active, not recruiting | USA | 0 |
NCT04103879 | Phase II | ECT-001 cord blood cells Cyclophosphamide + Fludarabine + Thiotepa Tacrolimus Cyclophosphamide + Fludarabine Mycophenolate mofetil | US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia | Active, not recruiting | USA | NLD | 0 |
NCT04145531 | Phase II | JZP-458 | An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) | Completed | USA | CAN | 0 |
NCT04225676 | Phase II | Tisagenlecleucel | Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL) | Terminated | USA | 0 |
NCT04323657 | Phase Ib/II | Cyclophosphamide + Fludarabine TC-110 T-cells | TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | Completed | USA | 0 |
NCT04329325 | Phase II | Dasatinib + Dexamethasone + Methotrexate Blinatumomab + Dasatinib + Methotrexate | Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | Active, not recruiting | USA | 0 |
NCT04334993 | Phase II | Blinatumomab | Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study | Recruiting | ISR | 0 |
NCT04475731 | Phase II | Ponatinib | Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse | Active, not recruiting | ITA | 0 |
NCT04501614 | Phase Ib/II | Ponatinib | A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | Completed | USA | POL | NLD | ITA | GBR | FRA | ESP | CZE | BRA | AUS | ARG | 4 |
NCT04524455 | Phase I | Dexamethasone AMG 404 + Blinatumomab | A Study of Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Acute Lymphoblastic Leukemia (ALL) | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | AUT | AUS | 0 |
NCT04530565 | Phase III | Cyclophosphamide + Dasatinib + Dexamethasone + Doxorubicin + Vincristine Sulfate Blinatumomab + Dexamethasone + Ponatinib + Prednisone Blinatumomab + Dasatinib + Dexamethasone + Prednisone Dasatinib Ponatinib Blinatumomab + Dexamethasone + Methotrexate + Ponatinib + Prednisone Blinatumomab + Dasatinib + Dexamethasone + Methotrexate + Prednisone Ponatinib + Prednisone Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Mesna + Methotrexate + Vincristine Sulfate Cytarabine + Methotrexate + Ponatinib Cytarabine + Dasatinib + Methotrexate Cyclophosphamide + Dexamethasone + Doxorubicin + Ponatinib + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Doxorubicin + Methotrexate + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Ponatinib + Vincristine Sulfate Dasatinib + Prednisone | Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults | Recruiting | USA | ISR | 1 |
NCT04684563 | Phase I | HuCART19-IL18 | huCART19-IL18 in NHL/CLL Patients | Recruiting | USA | 0 |
NCT04722848 | Phase III | Blinatumomab + Ponatinib Imatinib | Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL | Recruiting | ITA | 0 |
NCT04730349 | Phase Ib/II | Nivolumab + NKTR-214 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer (PIVOT IO 020) | Terminated | USA | ITA | FRA | ESP | DEU | AUS | 0 |
NCT04752163 | Phase Ib/II | Cyclophosphamide + Cytarabine + Dexamethasone + DS-1594b + Filgrastim + Mesna + Methotrexate + Vincristine Sulfate DS-1594b + Prednisone + Vincristine Sulfate DS-1594b Azacitidine + DS-1594b + Venetoclax Cytarabine + DS-1594b + Filgrastim + Leucovorin + Methotrexate Cytarabine + DS-1594b + Filgrastim + Leucovorin + Methotrexate + Rituximab | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | Completed | USA | 0 |
NCT04778579 | Phase II | ARI-0001 | Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy (CART19-BE-02) | Active, not recruiting | ESP | 0 |
NCT04845035 | Phase II | Asparaginase + Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Leucovorin + Mercaptopurine + Methotrexate + Ponatinib Mercaptopurine + Methotrexate Asparaginase + Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Doxorubicin + Methotrexate + Thioguanine + Vincristine Sulfate Leucovorin + Mercaptopurine + Methotrexate Asparaginase + Cyclophosphamide + Cytarabine + Daunorubicin + Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Asparaginase + Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Thioguanine + Vincristine Sulfate Mercaptopurine + Methotrexate + Ponatinib | Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | Withdrawn | USA | 0 |
NCT04865419 | Phase Ib/II | AZD0466 + Voriconazole AZD0466 | Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies | Terminated | USA | ITA | FRA | DEU | AUS | 1 |
NCT04872478 | Phase I | MRX-2843 | Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL | Recruiting | USA | 0 |
NCT04877522 | FDA approved | Asciminib Bosutinib Dasatinib Nilotinib Asciminib + Imatinib | Asciminib Roll-over Study | Recruiting | USA | TUR | ROU | POL | LBN | ITA | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BGR | AUT | ARG | 9 |
NCT04920968 | Phase II | Rituximab Obinutuzumab | Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 OVERALL (PALG ALL7) | Not yet recruiting | POL | 0 |
NCT04988555 | Phase Ib/II | DSP-5336 | A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation | Recruiting | USA | ITA | FRA | ESP | CAN | BEL | 4 |
NCT04996160 | Phase I | Bortezomib + Dexamethasone + Doxorubicin + Palbociclib | Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2) | Recruiting | USA | 0 |
NCT05044039 | Phase I | Duvelisib | Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy | Recruiting | USA | 0 |
NCT05054465 | Phase Ib/II | Navitoclax + Venetoclax | A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL (ITALLI001) | Not yet recruiting | ISR | 0 |
NCT05192889 | Phase Ib/II | Dexamethasone + Pegaspargase + Vincristine Sulfate Blinatumomab + Cytarabine + Dexamethasone + Hydrocortisone + Methotrexate + Venetoclax Cyclophosphamide + Cytarabine + Dexamethasone + Etoposide + Hydrocortisone + Leucovorin + Mercaptopurine + Methotrexate + Vincristine Sulfate Cytarabine + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Vincristine Sulfate Cytarabine + Dasatinib + Dexamethasone + Hydrocortisone + Methotrexate + Navitoclax + Pegaspargase + Venetoclax Dasatinib + Dexamethasone + Pegaspargase + Vincristine Sulfate Cytarabine + Dasatinib + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Vincristine Sulfate Cytarabine + Dexamethasone + Hydrocortisone + Leucovorin + Methotrexate + Navitoclax + Pegaspargase + Venetoclax + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Etoposide + Hydrocortisone + Leucovorin + Mercaptopurine + Methotrexate + Vincristine Sulfate Cytarabine + Dexamethasone + Hydrocortisone + Methotrexate + Navitoclax + Pegaspargase + Venetoclax Cytarabine + Hydrocortisone + Leucovorin + Mercaptopurine + Methotrexate Cytarabine + Dasatinib + Dexamethasone + Hydrocortisone + Leucovorin + Methotrexate + Navitoclax + Pegaspargase + Venetoclax + Vincristine Sulfate Blinatumomab + Cytarabine + Dasatinib + Dexamethasone + Hydrocortisone + Methotrexate + Venetoclax | Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax | Active, not recruiting | USA | 0 |
NCT05215405 | Expanded access | Navitoclax + Venetoclax | Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients With Relapsed or Refractory ALL or LL | Available | USA | 0 |
NCT05306301 | Phase II | Ponatinib | Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients | Recruiting | ITA | 0 |
NCT05326516 | Phase I | Revumenib | A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia | Completed | USA | CAN | 0 |
NCT05386576 | Phase I | Venetoclax | A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | Active, not recruiting | USA | 0 |
NCT05397496 | Phase I | PIT565 | Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies | Recruiting | USA | ITA | ISR | FRA | ESP | BEL | 2 |
NCT05400122 | Phase I | Aldesleukin + Vactosertib Cyclophosphamide + Fludarabine | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | Recruiting | USA | 0 |
NCT05418088 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19/CD20/CD22 CAR-T Cells | Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies | Recruiting | USA | 0 |
NCT05476770 | Phase I | Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Dexamethasone + Hydrocortisone + Methotrexate + Tagraxofusp-erzs + Vincristine Sulfate Azacitidine + Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Fludarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | Recruiting | USA | AUS | 0 |
NCT05480449 | Phase Ib/II | huCART19 | Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) | Recruiting | USA | 0 |
NCT05487651 | Phase I | KUR-502 | Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies (ANCHOR2) | Recruiting | USA | 0 |
NCT05507827 | Phase I | CD19/CD22 CAR T cells | Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-cell Acute Lymphoblastic Leukemia (ALL) | Recruiting | USA | 0 |
NCT05658640 | Phase Ib/II | Cyclophosphamide + Cytarabine + Dexamethasone + Trametinib | HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies (HEM-iSMART D) | Recruiting | SWE | NOR | NLD | ITA | ISR | IRL | GBR | FRA | FIN | ESP | DNK | DEU | CHE | BEL | AUT | 0 |
NCT05705570 | Phase I | Cyclophosphamide + Fludarabine MB-CART19.1 | A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies (CARTHIAE-1) | Not yet recruiting | BRA | 0 |
NCT05707273 | Phase I | Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine | CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission | Recruiting | USA | 0 |
NCT05740449 | Phase Ib/II | Decitabine + Navitoclax + Venetoclax | HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART A) | Withdrawn | NLD | 0 |
NCT05745714 | Phase Ib/II | Cyclophosphamide + Cytarabine + Dexamethasone + Ruxolitinib + Venetoclax | HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART C) | Not yet recruiting | NLD | 0 |
NCT05751044 | Phase Ib/II | Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Venetoclax | HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART B) | Not yet recruiting | NLD | 0 |
NCT05756322 | Phase Ib/II | LBS-007 | The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias | Recruiting | USA | AUS | 1 |
NCT05761171 | Phase II | Cytarabine + Fludarabine Pegaspargase + Prednisone + Vincristine Sulfate Calaspargase pegol-mknl + Prednisone + Vincristine Sulfate Revumenib Cytarabine + Hydrocortisone + Methotrexate Pegaspargase + Prednisolone + Vincristine Sulfate Calaspargase pegol-mknl + Prednisolone + Vincristine Sulfate | A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia | Recruiting | USA | 0 |
NCT05775406 | Phase I | KT-253 | Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors | Active, not recruiting | USA | 0 |
NCT05848687 | Phase Ib/II | Bortezomib Dexamethasone Blinatumomab Vorinostat Mercaptopurine Pegaspargase Methotrexate Ziftomenib Mitoxantrone | TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II | Recruiting | USA | CAN | 0 |
NCT05918692 | Phase I | BMF-500 | A Phase 1, Study of BMF-500 in Adults With Acute Leukemia | Recruiting | USA | 0 |
NCT06034561 | Phase II | Bortezomib + Dexamethasone + Doxorubicin + Methotrexate + Pegaspargase + Vincristine Sulfate | Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia | Recruiting | BRA | 0 |
NCT06061094 | Phase II | Blinatumomab + Ponatinib Imatinib Blinatumomab + Imatinib Ponatinib | Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT (GMALL-EVOLVE) | Recruiting | DEU | 0 |
NCT06101381 | Phase Ib/II | huCART19 | CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma (CARTHEDRALL) | Not yet recruiting | BRA | 0 |
NCT06208735 | Phase I | CLIC-2201 | CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies | Not yet recruiting | CAN | 0 |
NCT06227026 | Phase I | Anti-CD19 CAR-T cells | Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies (PRODIGY) | Recruiting | USA | 0 |
NCT06287944 | Phase I | Melphalan Fludarabine Sirolimus 225Ac-DOTA-Daratumumab Tacrolimus | 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome | Not yet recruiting | USA | 0 |
NCT06308588 | Phase II | Asciminib Asciminib + Blinatumomab | Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT06356922 | Phase Ib/II | [177Lu]Lu-PentixaTher | Study Assessing RLT Using [177Lu]Lu-PentixaTher for Relapsed/Refractory CXCR4+ Acute Leukemia. (PENTILULA) | Not yet recruiting | FRA | 0 |
NCT06390319 | Phase II | Cyclophosphamide + Cytarabine + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Vincristine Sulfate Bortezomib + Calaspargase pegol-mknl + Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Vincristine Sulfate Bortezomib + Calaspargase pegol-mknl + Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Methotrexate + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Nelarabine + Vincristine Sulfate Calaspargase pegol-mknl + Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Nelarabine + Venetoclax + Vincristine Sulfate Calaspargase pegol-mknl + Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Methotrexate + Venetoclax + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Nelarabine + Vincristine Sulfate Thioguanine Calaspargase pegol-mknl + Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Nelarabine + Vincristine Sulfate Calaspargase pegol-mknl + Cytarabine + Dasatinib + Daunorubicin + Dexamethasone + Hydrocortisone + Methotrexate + Vincristine Sulfate | Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) | Not yet recruiting | USA | 0 |
NCT06397027 | Phase I | Azacitidine + Venetoclax + Ziftomenib | A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias | Not yet recruiting | USA | 0 |
NCT06408194 | Phase I | Tisagenlecleucel Anti-CD22 CAR T cells | Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies | Recruiting | USA | 0 |
NCT06447987 | Phase I | Cetuximab Anti-CD19CAR-CD28-CD3zeta-EGFRt T-cells Cyclophosphamide + Fludarabine | Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT06575296 | Phase I | Revumenib | Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant | Not yet recruiting | USA | 0 |